When was Firefly Bio founded?

Firefly Bio was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Firefly Bio located?

Firefly Bio is headquartered in San Francisco, United States.

How many employees does Firefly Bio have?

As of Aug 31, 2026, the latest employee count at Firefly Bio is 24.

Is Firefly Bio a funded company?

Firefly Bio is a funded company, having raised a total of $94M across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 05, 2022.

When was the latest funding round of Firefly Bio?

Firefly Bio's latest funding was a $***** Series A round on Dec 18, 2023, with participation from 3 investors.

Where does Firefly Bio rank among its competitors?

Firefly Bio ranks 219th amongst 3317 active competitors, of which 1122 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Firefly Bio?

Firefly Bio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Firefly Bio - 2026 Company Profile, Team, Funding & Competitors

Firefly Bio is an acquired company based in San Francisco (United States), founded in 2022 by Carolyn Bertozzi. It operates as a Developer of antibody drug conjugates for the treatment of cancer. Firefly Bio has raised $94M in funding from Versant Ventures. The company has 3317 active competitors, including 1122 funded and 782 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of antibody drug conjugates for the treatment of cancer. The company uses potent catalytic protein degraders as the payloads of ADCs to develop class of therapeutics for a range of intracellular biological targets such as both solid and liquid tumors.

Website: fireflybiologics.com
Email ID: *****@fireflybiologics.com

Key Metrics

Founded Year

2022

Location

San Francisco, United States

Stage

Acquired

Total Funding

$94M in 3 rounds

Latest Funding Round

Series A, Dec 18, 2023, $*****

Investors

Versant Ventures & 3 more

Ranked

219^th among 3317 active competitors

Employee Count

24 as on Aug 31, 2026

Similar Companies

BeiGene & 643 more

Exit Details

Acquired by Johnson & Johnson (Jun 08, 2026)

View Firefly Bio's full profile

Firefly Bio got acquired by Johnson & Johnson on Jun 08, 2026 at an acquisition amount of $*****.

Click here to take a look at Firefly Bio's acquisition in detail

Firefly Bio has raised a total funding of $94M over 3 rounds. Its first funding round was on Mar 05, 2022. Its latest funding round was a Series A round on Dec 18, 2023 for $*****. 3 investors participated in its latest round. Firefly Bio has 4 institutional investors.

Here is the list of recent funding rounds of Firefly Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 18, 2023	2120260	Series A	6009787	8644667	3575107	8487094
Sep 01, 2022	7550276	Grant (prize money)	5382540	5970347	8290836	HHS
Mar 05, 2022	4257045	Grant (prize money)	3654664	6802820	3252668	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Firefly Bio's funding rounds and investors

The founders of Firefly Bio is Carolyn Bertozzi.

Here are the details of Firefly Bio's key team members:

Carolyn Bertozzi: Co-founder and Chief Technology Officer of Firefly Bio.

View details of Firefly Bio's Founder profiles and Board Members

Firefly Bio's employee count trend

Firefly Bio has 24 employees as of Aug 26. Here is Firefly Bio's employee count trend over the years:

Uncover Firefly Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Firefly Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Firefly Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
219th	Firefly Bio 2022, San Francisco (United States), Acquired	Developer of antibody drug conjugates for the treatment of cancer	$94M	Versant Ventures, Decheng Capital & 2 others	59/100